Acadia Pharma (ACAD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment
November 6, 2015 12:00 PM ESTCowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results with all eyes on PDP PDUFA and ADP enrollment.
Baral commented, "ACAD reported 3Q15 earnings and elaborated on initial steps for upcoming commercial... More
Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
November 6, 2015 9:43 AM ESTPiper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $39.00 (from $48.00).
Analyst Charles Duncan commented, "We're downgrading to Neutral following program updates that lower our conviction on near-term upside from the pima pipeline. New concerns center on a... More



